Psomagen, Inc.

Psomagen, Inc.

950200 · KQ · Healthcare / Diagnostics & Research

2,690.00KRW+10.00 (+0.37%)

Price History

Full chart

Market Stats

Previous Close2,680.00
Open2,710.00
Day Range2,665.00 – 2,795.00
52-Week Range2,380.00 – 4,690.00
Volume15.34K
Market Cap57.32B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta-0.17
50-Day Avg3,132.70
200-Day Avg3,329.35

About

Psomagen, Inc. engages in the provision omics solutions and contract laboratory services. The company's research services includes genomics, a study of gene sequence and expression; epigenomics, a study of epigenetic changes, such as chromatin assembly, histone modification, and DNA-protein interaction in a cell; single-cell analysis, research in suspensions, biological fluids, tissues, or cell populations; metagenomics, a study of genetic material from microorganisms in heterogeneous samples; transcriptomics, a study of RNA and its expression through sequencing, used to analyze the impact of gene expression on the biology of an organism; and proteomics, a study of all the expressed proteins in an organism (proteome). It also offers Bioinformatics, a software tool and pipeline that helps scientists in analyzing data; and provides clinical genetic testing, whole-genome, whole-exome, and sanger sequencing services. The company was formerly known as Macrogen Corp. and changed its name to Psomagen, Inc. in April 2019. Psomagen, Inc. was incorporated in 2004 and is headquartered in Wilmington, Delaware. Psomagen, Inc. is a subsidiary of Macrogen, Inc.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEOSu Hong
  • Employees87
  • HeadquartersCorporation Trust Center, Wilmington, DE, United States, 20850, Korea
  • Websitehttps://www.psomagen.com

Leadership

  • Su HongCEO & Director · b. 1980
  • Jun Ho LeeInternal Accounting Manager

Financials

Income Statement

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Revenue43.37B32.27B43.66B59.19B
Growth (%)--25.59%+35.29%+35.56%
Cost of Revenue31.30B24.81B34.09B44.70B
Gross Profit12.07B7.46B9.57B14.49B
Gross Margin27.84%23.13%21.92%24.48%
Operating Expense13.55B11.02B14.80B16.74B
Operating Income-1.47B-3.55B-5.23B-2.25B
Operating Margin-3.40%-11.01%-11.98%-3.81%
EBITDA3.05B-189.89M-585.41M2.04B
EBITDA Margin7.02%-0.59%-1.34%3.44%
Net Income-1.05B-4.29B-5.62B-2.98B
Net Income Margin-2.42%-13.29%-12.87%-5.04%
R&D1.94B1.35B1.09B1.06B
R&D as % of Total Revenue4.48%4.19%2.50%1.79%
Interest Expense242.02M219.19M504.07M978.30M
Interest Expense % of Total Revenue0.56%0.68%1.15%1.65%

Balance Sheet

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Assets49.20B44.60B55.44B49.78B
Total Liabilities13.52B12.35B25.15B24.07B
Total Equity35.68B32.22B30.76B27.29B
Cash14.88B3.02B4.54B8.36B

Cash Flow

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-288.74M1.59B3.30B834.43M
Capital Expenditure3.64B5.56B4.93B901.68M
Free Cash Flow-3.93B-3.97B-1.64B-67.25M
FCF to OCF1360.93%-249.97%-49.60%-8.06%

Key Statistics & Ratios

Market Cap57.32B
Enterprise Value53.37B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.94
Price / Book1.88
Revenue (TTM)60.70B
Gross Profit (TTM)15.52B
EBITDA3.94B
Profit Margin-2.62%
Operating Margin-5.56%
Return on Equity-10.39%
Return on Assets-1.29%
Shares Outstanding19.24M
Shares Float8.28M
Beta-0.17
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%